

Beloranib safe, efficacious for weight loss in obesity

22 May 2015



Several authors disclosed employment or other financial ties to Zafgen, the developer of beloranib.

More information: [Abstract](#)
[Full Text](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

(HealthDay)—Beloranib seems efficacious and safe for weight loss in obese patients, according to a study published in the June issue of *Diabetes, Obesity and Metabolism*.

Dennis D. Kim, M.B.A., from Zafgen Inc. in Cambridge, Mass., and colleagues examined the efficacy, safety, and tolerability of beloranib treatment for obesity. One hundred forty-seven participants were randomized to beloranib suspension (0.6, 1.2, and 2.4 mg) or [placebo](#), administered subcutaneously for 12 weeks. No diet or exercise advice was given to the participants.

The researchers found that beloranib resulted in dose-dependent progressive [weight loss](#) of 5.5 ± 0.5 kg for 0.6 mg, 6.9 ± 0.6 kg for 1.2 mg, and 10.9 ± 1.1 kg for 2.4 mg doses, compared with 0.4 ± 0.4 kg with placebo (all P

"In this 12-week phase II study, beloranib produced clinically and statistically significant weight loss and corresponding improvements in cardiometabolic risk factors," the authors write. "These findings represent a novel mechanism for producing clinically meaningful weight loss."

APA citation: Beloranib safe, efficacious for weight loss in obesity (2015, May 22) retrieved 29 August 2022 from <https://medicalxpress.com/news/2015-05-beloranib-safe-efficacious-weight-loss.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.